Menopausal hormone therapy after breast cancer: a meta-analysis and critical appraisal of the evidence

Col, Nananda F; Kim, Jung A; Chlebowski, Rowan T

doi:10.1186/bcr1035

Breast Cancer Research

Table 1 Characteristics of 1316 users and 2839 nonusers of hormone therapy

From: Menopausal hormone therapy after breast cancer: a meta-analysis and critical appraisal of the evidence

Study	Treatment	n	Mean age (years)	Stage	Nodal status	ER status	PgR status	Mean DFI before HT (months)	Estrogen alone (%)	Mean duration of HT (months)	Mean follow-up after HT (months)	Recurrences (n)	Deaths, all cause (n)	Deaths, primary tumor (n)
Randomized trials
Marsden et al. (2000; n = 100) [20]	HT	51^a	58^b	NR	NR	NR	NR	40^b	NR	6	NR	2	NR	NR
	No HT	49^a	55^b	NR	NR	NR	NR	36^b			NR	1	NR	NR
Holmberg et al. (2004; n = 345) [9]	HT	174	55.5	NR	25.9% (38) positive	86 positive^c	NR	31.2^b	NR	24	25.2^b	26	5	3
	No HT	171	55.0	NR	21.4% (31) positive	73 positive^c	NR	32.4^b			25.2^b	7	4	4
Observational studies
Ursic-Vrscaj and Bebar (1999; n = 63) [27]	HT	21^d	47^b	1 G1 10 G2 7 G3	14 negative, 7 positive	5 positive, 16 negative	8 positive, 13 negative	62	4.8	28	38^g	4	0^g	0
	No HT	42^d	48.2	7 G1 17 G2 11 G3	28 negative 14 positive	18 positive, 22 negative	22 positive, 18 negative	NR			38^g	5	1^g	1
DiSaia et al. (2000; n = 487) [22]	HT	125	55.7	17 DCIS 52 stage I 27 stage II 10 stage III 1 stage IV	NR	NR	NR	46^b	28	22^b	92.1^g	NR	4^g	NR
	No HT	362	55.9	NR	NR	NR	NR	NR			90.6^g	NR	57^g	NR
O'Meara et al. (2001; n = 869) [36]	HT	174^d	63.6^e	91 stage I 51 stage II 20 stage I/II 10 stage III 2 stage II/III	128 negative, 31 positive	84 positive, 39 negative	71 positive, 45 negative	47.7^e	79	15^b	44.4^b,f	16	17	5
	No HT	695^d	63.6^e	403 stage I 246 stage II 3 stage I/II 42 stage III 1 stage II/III	470 negative, 175 positive	409 positive, 137 negative	311 positive, 206 negative	47.7^e			44.4^b,f	101	115	59
Beckmann et al. (2001; n = 185) [24]	HT	64	NA	37 T1 19 T2 8 T3/4	44 negative, 20 positive	31 positive, 33 negative	34 positive, 30 negative	0	NA	33^b	37^b	6	4	NR
	No HT	121	NA	62 T1 42 T2 17 T3/4	76 negative, 45 positive	48 positive, 73 negative	48 positive, 73 negative	0			42^b	17	15	NR
Marttunnen et al. (2001; n = 131) [26]	HT	88	53.4	3 DCIS 67 T1 17 T2 1 T3	72 negative, 10 positive	57 positive, 15 negative	54 positive^g, 13 negative^g	50.4	38.6	30	30	7	2	2
	No HT	43	52.8	1 DCIS 29 T1 11 T2 2 T3	30 negative, 13 positive	29 positive, 9 negative	30 positive^g, 7 negative^g	50.4			31.2	5	3	3
Durna et al. (2002; n = 1122) [23]	HT	286	56.8^b	180 stage I 64 stage II 22 stage III/IV	NA	NR	NR	12^b	5.9	21^b	69.6^b	44	16	13
	No HT	836	64.7^b	470 stage I 191 stage II 120 stage III/IV	NA	NR	NR	NR			61.2^b	247	199	122
Vassilopoulou-Sellin et al. (2002; n = 299) [21]	HT	56^h	56^b	9 <1 cm 30 1–2.5 cm 15 >2.5 cm	35 negative, 13 1–3, 6 >3	37 negative	NR	105.6	100	30 >5 years, 20 2–5 years, 6 2 years	71	2	1	0
	No HT	243^h	53^b	38 <1 cm 134 1–2.5 cm 67 >2.5 cm	133 negative, 70 1–3, 33 >3	164 negative	NR	99.6			NR	33	2	1
Decker et al. (2003; n = 554) [25]	HT	277	57.4^b	84 DCIS 124 stage I 47 stage IIA 19 stage IIB 3 stage IIIA	NR	100 positive, 54 negative	63 positive, 46 negative	43.3	48.7	44.4	49.7	30	7	5
	No HT	277	59.0^b	84 DCIS 124 stage I 47 stage IIA 19 stage IIB 3 stage IIIA	NR	121 positive, 35 negative	73 positive, 42 negative	NR			45.6	35	17	9
Summary
Randomized trials	HT	225	56.07		38 positive	86 positive		33.19		19.92	25.20	28	5	3
	No HT	220	55.00		31 positive	73 positive		33.20			25.20	8	4	4
Observational studies	HT	1091	56.98		293 negative, 87 positive	277 positive, 194 negative	230 positive, 147 negative	37.70	40.4	28.02	57.46	109	51	25
	No HT	2619	60.87		737 negative, 350 positive	625 positive, 440 negative	484 positive, 346 negative	54.01			57.02	443	409	195
All combined	HT	1316	56.82		293 negative, 125 positive	363 positive, 194 negative	230 positive, 147 negative	36.93	40.4	26.58	53.03	137	56	28
	No HT	2839	60.39		737 negative, 381 positive	698 positive, 440 negative	484 positive, 346 negative	50.55			54.88	451	413	199

^aExcluding stage III/IV patients. ^bMedian value. ^cRefers to hormone receptor status; specific data concerning estrogen receptor (ER) and progesterone receptor (PgR) status were not reported. ^dExcluding patients with ductal carcinoma in situ (DCIS). ^eWeighted mean. ^fFor recurrence only; follow-up for mortality was 55.2 months. ^gPersonal communication. ^hExcluding DCIS, stages III and IV, and ER-positive patients. DFI, disease-free interval; HT, hormone therapy; NA, not able to calculate; NR, not reported.

Back to article page

ISSN: 1465-542X

Contact us

Submission enquiries: journalsubmissions@springernature.com